At Astria Therapeutics, our team is focused on bringing therapies with the potential to improve the quality of life to patients and families affected by Hereditary Angioedema (HAE) and rare allergic and immunological diseases$1. .$1
11 - 50
π° $100M Post-IPO Equity on 2022-12
January 10
π‘ Remote β New York
β° Full Time
π‘ Mid-level
π Senior
π€ Developer Relations (DevRel)